Showing 1‐20 of 500
01 Jun 2023
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs) Acquisition will further strengthen Lonza’s bioconjugates offering...
16 May 2023
Lonza Prices EUR 500 Million Straight Bond with a 3.875% Coupon
Basel, Switzerland, 16 May 2023 – Lonza Finance International NV, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a EUR 500 million...
10 May 2023
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Robust commercial demand, with softer early-stage demand due to biotech funding constraints Growth project portfolio progressing in line with plan Outlook 2023 reiterated,...
05 May 2023
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Shareholders re-elected all existing members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors A dividend of CHF 3.50 per share...
20 Apr 2023
Lonza Increases Straight Bond by CHF 150 Million
Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued...
31 Mar 2023
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong...
29 Mar 2023
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing The line is fully...
27 Mar 2023
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of...
16 Feb 2023
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates The Visp (CH) investment...
08 Feb 2023
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million...
25 Jan 2023
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth CHF 2.0 billion CORE EBITDA resulted in a margin of 32.1% Growth investment continues as 2022 CAPEX...
01 Nov 2022
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs Innovative Capsugel® Enprotect™ capsule can...
06 Oct 2022
Two Cell and Gene Therapies Manufactured at Lonza Houston Reach US FDA Approval in Q3 2022
The two recent FDA approvals of ZYNTEGLO® (betibeglogene autotemcel) and SKYSONA® (elivaldogene autotemcel), both developed by bluebird bio, mean that Lonza’s Houston (US) site...
14 Sep 2022
Lonza Expands HPAPI Multipurpose Suite for Payload-Linker Manufacturing in Visp (CH)
Lonza adds further capacity for the manufacturing of antibody-drug conjugate (ADC) payloads Expanded multipurpose suite supports payload-linkers development and manufacturing...
Cell & Gene
12 Sep 2022
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022,...
06 Sep 2022
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM)...
22 Jul 2022
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8% CER sales growth
01 Jul 2022
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)
Lonza to build a new large-scale, commercial drug product fill and finish facility to support customers across the entire product life cycle Lonza will invest approximately...
01 Jul 2022
Maria Soler Nunez appointed as Head, Group Operations
Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her...
Cell & Gene
24 Jun 2022
Lonza and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza’s Patents
Lonza and Adva have entered into a license agreement ensuring broad access to smart automation technology With this agreement, Lonza and Adva have resolved their related...